ImmunityBio Hit with Securities Class Action Over Alleged Drug Promotion Violations

What happened

ImmunityBio faces a new securities class action lawsuit alleging the company violated drug promotion laws by misbranding ANKTIVA and promoting an unapproved route of administration. The suit covers investors who bought shares between January 19 and March 24, 2026, a period that saw the stock surge on revenue momentum before plunging after the FDA's March 13 warning letter. The DeepValue report had already flagged the FDA promotional enforcement as a key risk, but the lawsuit crystallizes the legal overhang for shareholders during that window. The company's commercial ramp now carries the added weight of litigation that could distract management and amplify settlement or judgment costs.

Implication

The lawsuit raises the bar for a bullish thesis: ImmunityBio must not only show sustained ANKTIVA revenue growth and compliance containment but also navigate securities litigation that could lead to material financial penalties or settlements. The class period aligns with the stock's run-up and subsequent FDA-driven drop, making it likely that plaintiff attorneys will pursue discovery aggressively. Investors should wait for at least two consecutive quarters of >10% QoQ revenue growth and no further FDA or legal escalations before considering a position, given the heightened risk of dilution from financing needs now compounded by potential litigation costs.

Thesis delta

The bear case probabilities increase by 5-10% as the securities class action adds a third thesis breaker: material legal liability or settlement costs beyond the existing compliance and financing risks. The base case now requires not only revenue growth and regulatory containment but also defense against a lawsuit that could further pressure management attention and cash reserves.